表达IFN-γ的重组乳酸乳球菌的构建及其临床效果评价OA

Interferon-γ(IFN-γ)exhibits broad-spectrum antiviral activity and plays an important role in animal husbandry.This study aimed to construct a recombinant lactic acid bacterium expressing IFN-γ and evaluate its safety and therapeutic effect in clinical diarrheal diseases.Through molecular cloning technology,the goat IFN-γ gene was successfully inserted into the target plasmid pNZ8149,and the recombinant plasmid pNZ8149-IFN-γ was constructed.Furthermore,the recombinant Lactococcus lactis pNZ8149-IFN-γ/NZ3900(rL.lactis-IFN-γ)was successfully constructed.Methods such as restriction enzyme digestion identification,bacterial liquid PCR,and DNA sequencing were used to verify the correctness of the recombinant plasmid,and it was identified by Western blot that the recombinant strain could successfully express IFN-γ.The recombinant probiotic was evaluated for safety in animals such as cat(Felis silvestris catus)and goat(Capra hircus),and the results showed that the recombinant strain had no obvious toxicity to the experimental animals.The effect of the recombinant probiotic preparation was evaluated through naturally diseased animals(calves(Bos taurus)with persistent diarrhea,forest musk deer(Moschus berezovskii)with diarrhea,and dogs(Canis lupus familiaris)with gastroenteritis).The results showed that the recombinant probiotic preparation had a significant effect on the treatment of diarrhea in different species.The results of this study indicated that the recombinant lactic acid bacterium expressing IFN-γ could not only be safely applied in clinical practice,but also had a good effect in the treatment of animal diarrheal diseases.This study provides a new treatment strategy for animal diarrheal diseases and other related diseases caused by viral infections.